

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-56. (cancelled)

57. (currently amended) A method for inhibiting the growth of a ~~malignant B-cell *in vivo*~~ a human hairy-cell leukemia cell that expresses a CD22 molecule on the surface of the cell, said method comprising:

contacting said human hairy-cell leukemia cell *in vivo* ~~malignant B-cell~~ with an effective amount of a recombinant immunoconjugates ~~*in vivo*~~ comprising a *Pseudomonas* exotoxin PE38 ~~a therapeutic agent or a detectable label~~ covalently linked at its amino terminus to an RFB4 disulfide-stabilized Fv (dsFv) having a variable heavy chain (V_H) comprising SEQ ID NO:2 in which a Cys residue is substituted for Arg at position 44; and a variable light chain (V_L) comprising SEQ ID NO:4 in which a Cys residue is substituted for Gly at position 100, thereby inhibiting the growth of the ~~malignant B-cell~~ human hairy-cell leukemia cell.

58-72. (cancelled)